Pfizer Inc. announced the acquisition of Global Blood Therapeutics, Inc., a leading developer and provider of treatments for SCD patients. With this acquisition, Pfizer aims to advance these treatments in the rare hematology space of sickle cell diseases.
F. Hoffmann-La-Roche Ltd. Announced the approval of the European Commission for the expansion of Hemlibra. With this expansion, Roche aims to include bleeding episodes in hemophilia A patients without the use of factor VII inhibitors
Author Credits: Radhika Gupta, Shivam Bhutani